It is known that SPARC gates VEGF-A signal transduction towards KDR, the primary angiogenic VEGF receptor. We sought to determine whether inhibition of SPARC activity using anti-SPARC peptide could inhibit laser-induced CNV by promoting binding of VEGF-A to FLT-1. We created anti-SPARC L-peptide and retro-inverso anti-SPARC D-peptide. Anti-SPARC peptides or PBS were injected intravitreally 1 day before or after laser induction. Intravitreal injection of anti-SPARC L-peptide 1 day before laser induction promotes FLT-1 phosphorylation and inhibited laser-induced CNV and anti-SPARC D-peptide had no effect. Injection 1 day after laser injury did not affect size of laser-induced CNV. Inhibition of SPARC activity could be complementary to existing anti-CNV therapy.
Introduction
Neovascularization, the abnormal growth of new blood vessels, plays an important role in many diseases, including cancer and blindness (Bellner et al., 2008; Epstein, Stulting, Hendricks, & Harris, 1987; Folkman, 1990) . In patients with age-related macular degeneration (AMD) choroidal neovascularization (CNV) is a principal cause of blindness (Smith et al., 2001) . CNV grows from the choroid into the subretinal space. These blood vessels may bleed into the subretinal space resulting in edema and tissue damage. Vascular endothelial growth factor (VEGF) has been found to be a potent stimulator of CNV (Amin, Puklin, & Frank, 1994; Ng & Adamis, 2005) . FLT-1 (also referred as VEGF receptor-1) and KDR (also referred as VEGF receptor-2) are the principal VEGF receptors and are critically involved in neovascularization and angiogenesis (de Vries et al., 1992; Matsumoto et al., 2005; Shibuya, 1995 Shibuya, , 2006 Shibuya & Claesson-Welsh, 2006) . Generally, activation of KDR by VEGF promotes angiogenesis. On the other hand, FLT-1 signaling has been reported to both promote (Carmeliet et al., 2001; Hiratsuka et al., 2001 ) and suppress angiogenesis (Bussolati et al., 2001; Kearney et al., 2002) , depending on the tissue and context. In addition, due to alternative splicing, the FLT-1 gene produces membrane-bound FLT-1 and soluble FLT-1 isoforms. Soluble FLT-1 has a partial extracellular domain of membrane FLT-1 and a unique C-terminal peptide. Soluble FLT-1 binds VEGF-A as an extracellular antagonist and blocks its signaling. It is known that soluble FLT-1 is vital to corneal avascularity (Ambati et al., 2006) . While VEGF is critical to angiogenesis, VEGF overexpression alone does not induce CNV in mice (Oshima et al., 2004) . This indicates other cellular or extracellular components may play key roles in the development of CNV.
In this study, we focused on the role of SPARC (secreted protein, acidic and rich in cysteine; also known as BM-40 and osteonectin) in laser-induced CNV, a well-established model for age-related macular degeneration. SPARC belongs to the matricellular family that mediates cell-matrix interactions, which affect biological functions including proliferation, survival, adhesion and migration (Bornstein & Sage, 2002) . SPARC binds to VEGF and inhibits tyrosine phosphorylation of FLT-1 but not KDR (Kupprion, Motamed, & Sage, 1998) . Nozaki et al. demonstrated reduced SPARC temporarily after laser injury in the choroid, creating a window of permissibility for VEGF binding to FLT-1. FLT-1 activation inhibits signal transduction of KDR through SHP-1 and can decrease laser-induced CNV volume . Based on these earlier studies we hypothesized inhibition of SPARC activity could reduce or prevent laser-induced CNV. Based on this hypothesis we created anti-SPARC peptides to bind SPARC by phage-screening and examined the effect of anti-SPARC peptides on a laser-induced CNV model.
Methods

Phage-screening for anti-SPARC peptide
The Ph.D.™ Phage Display Peptide Library Kit (New England Biolabs, Ipswich, USA) was used for in vitro biopanning procedures. This ligand screening system is based on a library of random peptide 7-mers fused to a minor coat protein, pIII, of the filamentous coliphage M13. Phage selection in vitro was performed according to the manufacture's protocol. SPARC recombinant proteins were coated on 96-well plates in 0.1 M NaHCO 3 coating buffer and incubated overnight at 4°C. The next day the plates were washed with 0.1% Tween-20 in TBS (TBST), followed by blocking in 3% BSA for 1 h. In the first round of biopanning, 2 Â 10 11 phage (100 equivalents of original library) were added to each well with 0.1% bovine serum albumin (BSA) and incubated for 1 h at room temperature. The plates were then washed 10 times with TBST. After washing, 100 ll of 0.2 M Glycine-HCl (pH 2.2) and 1 mg/ml BSA were added to the wells to elute recombinant protein bound phage. One microliter of eluted phage was tittered on LB/IPTG/Xgal plates and blue plaques were counted and phage titer was determined. The remaining phage was amplified using ER2738 E. Coli in LB-Tet according to the manufacture's instructions. For the following steps 2 Â 10 11 pfu plaques were use. We performed four cycles of binding and amplification on the previously eluted and amplified phage to enrich the pool in favor of binding sequences.
Surface plasmon resonance
Interaction between anti-SPARC L-or D-peptide and SPARC was determined by Biacore 2000 (GE Healthcare/Biacore, Uppsala, Sweden). SPARC from PYS-2 cell (sigma) was immobilized using standard amine-coupling chemistry to a density of 2100 resonance units (RU). As a control, we also immobilized 2100 RU carbonic anhydrase. The peptides were tested in duplicate in a two-fold dilution series for binding to the protein surfaces. Fitting the responses to a simple binding isotherm yielded the affinities.
Intravitreal peptide injection
Wild-type C57/BL6 mice were purchased from Jackson Laboratory. Mice (6-8 weeks old) were anesthetized by intraperitoneal injection of Ketaset Ò (50 mg/kg; Wyeth, Fort Dodge, USA) and xylazine (Tranqui Ved, 10 mg/kg; VEDCO, St. Joseph, USA). Anti-SPARC L-peptide (20 ng or 2 lg), anti-SPARC D-peptide (20 ng or 2 lg), or PBS, as a control, was injected into the vitreous cavity in a total volume of 1 ll with 33-gauge micro syringe (Hamilton Company, Reno, USA).
Laser induced choroidal neovascularization
Laser photocoagulation (532 nm, 100 mV, 100 ms, 50 lm; NI-DEK MC-4000) was performed on both eyes (2-5 spots per eye) as described (Sakurai, Anand, Ambati, van Rooijen, & Ambati, 2003; . After enucleating the eyes, sclera/choroid/RPE complex were fixed in 4% paraformaldehyde for 2 h at 4°C. After blocking in 5% FBS/PBS with 0.02% tritonX-100 and 2 mM MgCl 2 , samples were stained with 5 lg/ml Alexa488 conjugated isolectin GS-IB4 (Invitrogen Corporation, Carlsbad, USA) overnight. After washing the samples were flat mounted on glass slides. CNV volume was measured by scanning laser confocal microscopy (Olympus America Inc., Center Valley, USA).
Immunoprecipitation and Western Blot
After euthanizing the mice, RPE/choroid complex was separated from sclera under a stereomicroscope and placed in 200 ll of RIPA buffer (Sigma-Aldrich, St. Louis, USA) containing protease inhibitor cocktail (Roche Diagnostics Corporation, Indianapolis, USA) and Halt™ phosphatase inhibitor (Fisher Scientific, Pittsburg, USA). After homogenization with a sonic dismembrator (Fisher Scientific, Pittsburg, USA), 150 ll samples were subjected to immunoprecipitation for FLT-1 or KDR. For immunoprecipitation we used protein G or A coated magnetic beads (Invitrogen Corporation, Carlsbad, USA) and mouse anti-FLT-1 antibody or rabbit anti-KDR antibody (Abcam Inc., Cambridge, USA) following manufacture's instructions. The proteins were eluted with Laemmli buffer for 10 min at 70°C and resolved by SDS-PAGE (8%) under reducing conditions. The protein was transferred to a nitrocellulose membrane and incubated for 1 h with blocking buffer (3% BSA and 0.05% Tween-20 in TBS) then incubated with anti-phospho-FLT-1(Tyr1213) antibody (1:1000, Millipore, Billerica, USA) or anti-tyrosine phosphorylation antibody in blocking buffer for 1 h at room temperature. The membrane was washed once in TBST (0.05% Tween-20/TBS) and twice in TBS. Finally, the membrane was incubated with the appropriate secondary HRP-linked antibody in blocking buffer for 30 min at room temperature. After washing once with TBST and thrice with TBS, the bands were illuminated by an ECL-PLUS Western Blot detection kit (Amersham Biosciences, Pittsburg, USA) and detected by FOTO/Analyst Electronic Imaging Systems (Fotodyne Inc., Hartland, USA).
Statistics
Data are shown as mean ± sem or sd. P values were calculated using student's t-test.
Results
Generation of anti-SPARC peptide
SPARC is expressed in retinal pigment epithelium (RPE) (Hiscott et al., 2002) . In addition, we detected SPARC in the cornea, lens and retina by immunohistochemistry, although the signal intensities less than RPE (data not shown). Laser-induced CNV occurs from the choroid to the retina through the RPE. The RPE is thought to play a key role in early and late stage AMD (Schmitz-Valckenberg, Fleckenstein, Scholl, & Holz, 2009 ). We had previously determined the probable mode of VEGF-SPARC binding via computational molecular docking (Chandrasekaran, Ambati, Ambati, & Taylor, 2007) as well as the relevance of that interaction in gating VEGF angiogenic vs. anti-angiogenic effects in a laser-induced CNV model . We therefore hypothesized that inhibiting SPARC binding of VEGF would inhibit laser-induced CNV.
To inhibit SPARC activity we employed a small peptide, as we hypothesized small molecules would enter the RPE more efficiently and induce less inflammation than antibodies. In addition we thought a small peptide would limit only SPARC activity to VEGF effectively. To create the peptide blocking SPARC activity we performed phage-screening against SPARC and obtained the L-peptide sequence SMPTYNK. There were two small regions of VEGF predicted to have significant protein-protein interactions with SPARC (one around residue 200, and another around 260-270; amino acid number according to Genbank file AAH65522) (Chandrasekaran et al., 2007) . We compared L-peptide SMPTYNK with these regions of VEGF and found two possible matches (Fig. 1) . Results from X-ray crystallographic analysis and mutagenesis studies concluded FMDVYQR is a helix near the binding site of VEGF to FLT-1 and KDR Wiesmann et al., 1997) . From the 3-D docking model of VEGF-SPARC binding (Chandrasekaran et al., 2007) Met (M) and Tyr (Y) residues project on the same side of the helix forming an MXXY motif, a feature of SMPTYNK. We believe this part of VEGF-A binds to SPARC and inhibits SPARC activity. Based on these considerations we selected L-KFMDVYNR as anti-SPARC L-peptide. In addition to anti-SPARC L-peptide, we synthesized anti-SPARC Dpeptide (retro-inverso peptide, D-RNYVDMFK), sequenced based on anti-SPARC L-peptide. To confirm if anti-SPARC L-peptide and Dpeptide bind to SPARC we measured the interaction by surface plasmon resonance (SPR ; Table) . We found the interaction between SPARC and anti-SPARC L-peptide or D-peptide exists although the interactions were weak.
Anti-SPARC L-peptide injection before laser photocoagulation inhibits laser CNV volume
To determine if anti-SPARC peptide decreases laser CNV volume in mice we injected anti-SPARC L-peptide or D-peptide at 20 ng and 2 lg into the intravitreous cavity. One day after the injections we performed 2-5 spots of laser photocoagulation in each eye. After 10 days the volumes of laser CNV were measured by confocal microscopy. Fig. 2 (Fig. 2g) . The sample number of each group was 10-15 laser-CNV spots.
Anti-SPARC L-peptide injections after laser photocoagulation do not affect laser CNV volume
We injected anti-SPARC L-or D-peptide at 20 ng or 2 lg after 1 day of laser photocoagulation. After 10 days the volumes of laser CNV were measured (Fig. 3) . Unlike anti-SPARC L-peptide injection before laser photocoagulation, we could not detect a significant effect. The sample number of each group was 10-15 laser-CNV spots.
Anti-SPARC L-peptide increased phosphorylation of FLT-1 and decreased phosphorylation of KDR after 1 day of laser photocoagulation in vivo
Because it was reported that SPARC sequesters phosphorylation of FLT-1 by VEGF (Kupprion et al., 1998) , we investigated whether Fig. 1 . Potential matches of phage display derived L-peptide SMPTYNK to the VEGF protein sequence. Underlined residues in VEGF are predicted to be sites of interaction with SPARC (Table 1 and the reference Chandrasekaran et al. (2007) ) by H-bonding or predicted hydrophobic interactions (e.g. FM near N-terminus shown). Exact matches are shown in bold, similarities in italics. Note that NK in the peptide is functionally similar to QR in VEGF. The partial VEGF-A sequence shown is numbered according to Genbank file AAH65522.
Table 1
Interaction between anti-SPARC peptides and SPARC protein measured by surface plasmon resonance. anti-SPARC peptides would decrease SPARC activity in RPE/choroid and eventually decrease phosphorylation of FLT-1. One day after anti-SPARC L-peptide, D-peptide or PBS injection we performed laser photocoagulation. One to two days later RPE/choroid was carefully dissected from sclera and we examined phosphorylation of FLT-1 and KDR by Western Blot (Fig. 4) . Western Blot showed anti-SPARC L-peptide increased phosphorylation of FLT-1 after 1 day of laser photocoagulation compared with PBS or anti-SPARC D-peptide injection. Two days after laser photocoagulation there were no significant differences in phosphorylation of FLT-1. Conversely, phosphorylation of KDR was decreased 1 day after but not 2 days after laser photocoagulation.
Discussion
VEGF, as a potent inducer of CNV, has been studied and its inhibition by anti-VEGF antibody (ranibizumab) has shown improvement of AMD patients' vision (Chang et al., 2007; Rosenfeld et al., 2006) . Despite this discovery, its application has been limited to advanced stages. We believe treatment at earlier stages will be necessary to decrease CNV growth or prevent CNV. In addition, clinical trials of pegaptanib in AMD patients showed an inverse therapeutic dose response (Gragoudas, Adamis, Cunningham, Feinsod, & Guyer, 2004) . This indicates over-inhibition of VEGF may lead to an adverse effect and we hypothesized that the treatment of other targets related to VEGF may be helpful for AMD patients.
In addition to VEGF regulation, several other growth factors are affected by SPARC. For example, the stimulation of platelet-derived growth factor induced proliferation of human arterial vascular smooth muscle is inhibited in the presence of SPARC (Motamed et al., 2002) . Transforming growth factor b is also regulated by SPARC (Francki et al., 2004) .
In this study we focused on SPARC activity as it relates to VEGF. We designed a small peptide to inhibit SPARC by phage-screening and previous computational analysis predictions (Chandrasekaran et al., 2007) . Intravitreal injection of L-anti-SPARC peptide 1 day before laser photocoagulation prevented laser-induced CNV growth. However, we could not find a significant difference in laser-induced CNV when we injected anti-SPARC peptide after laser injury. This may be due to two reasons. (1) Previous studies reported that 1 day after laser photocoagulation SPARC decreased in RPE/choroid temporarily, but recovered the next day . Hence, injection of anti-SPARC L-peptide after laser injury may not have a target as SPARC had already declined. (2) This may indicate SPARC regulation is operative in the initial phases of laser injury and determines the fate of cells in CNV through FLT-1 and KDR signaling. This concept is supported by Western Blot analysis of phosphorylation of FLT-1 and KDR (Fig. 4) . In eyes injected with anti-SPARC L-peptide 1 day before laser injury, phosphorylation of FLT-1 increased. Conversely, KDR phosphorylation decreased 1 day after laser photocoagulation. We could not detect differences in phosphorylation of FLT-1 and KDR in eyes treated 2 days after laser photocoagulation. Alternatively, it is possible that SPARC function may change in response to injury (Arnold & Brekken, 2009) .
Although surface plasmon resonance showed low interaction between SPARC and anti-SPARC L-peptide, anti-SPARC L-peptide injection 1 day before laser photocoagulation reduced laser-induced CNV volume. It is possible that our dose of anti-SPARC L-peptide may overcome low binding affinity, further underlining the importance of SPARC at the initial stages of laser-induced CNV.
We successfully prevented laser-induced CNV using anti-SPARC L-peptide, but anti-SPARC D-peptide, which interacts with SPARC as much as anti-SPARC L-peptide did not inhibit CNV compared with PBS injection 1 day before or after laser photocoagulation. It is unclear why the D-peptide did not exert an inhibitory effect; one possibility is that there may be L-peptide specific transporters which enable transport of intravitreal peptides across the retina to sites of injury. Alternatively, there may be subtle steric interference points in the in vivo extracellular matrix blocking the anti-SPARC D-peptide activity. Fig. 4 shows that anti-SPARC L-peptide, but not anti-SPARC D-peptide, promoted phosphorylation of FLT-1 and decreased phosphorylation of KDR. This suggests that anti-SPARC D-peptide may bind to SPARC but not inhibit SPARC-VEGF interactions in vivo.
The clinical relevance of finding anti-SPARC intervention to be most effective immediately prior to laser injury in a murine model will depend on progress in assessing SPARC levels in macular degeneration patients. Patients with normal or above-normal SPARC levels may benefit from a combination of anti-SPARC plus anti-VEGF therapy.
In summary, we have shown that inhibition of SPARC by anti-SPARC L-peptide prior to laser photocoagulation reduces the volume of laser-induced CNV and that this is associated with increased phosphorylation of FLT-1 and decreased phosphorylation of KDR. Our results also confirm that SPARC plays a key role in the initial stages of laser-induced CNV. This may lay the foundation for anti-SPARC therapy to complement existing treatments for AMD.
